1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Premenstrual Dysphoric Disorder (PMDD) Global Clinical Trials Review, H2, 2015

Premenstrual Dysphoric Disorder (PMDD) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Premenstrual Dysphoric Disorder (PMDD) Global Clinical Trials Review, H2, 2015" provides an overview of Premenstrual Dysphoric Disorder (PMDD) clinical trials scenario. This report provides top line data relating to the clinical trials on Premenstrual Dysphoric Disorder (PMDD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Premenstrual Dysphoric Disorder (PMDD) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Premenstrual Dysphoric Disorder (PMDD) to Women's Health Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Premenstrual Dysphoric Disorder (PMDD) to Women's Health Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 48
Abbreviations 48
Definitions 48
Research Methodology 49
Secondary Research 49
About GlobalData 50
Contact Us 50
Disclaimer 50
Source 50

List of Tables
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials by Region, 2015* 6
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2015* 10
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 13
Proportion of Premenstrual Dysphoric Disorder (PMDD) to Women's Health Clinical Trials, G7 Countries (%), 2015* 14
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Premenstrual Dysphoric Disorder (PMDD) to Women's Health Clinical Trials, E7 Countries (%), 2015* 17
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 25
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

List of Figures
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2015* 10
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 13
Proportion of Premenstrual Dysphoric Disorder (PMDD) to Women's Health Clinical Trials, G7 Countries (%), 2015* 14
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Premenstrual Dysphoric Disorder (PMDD) to Women's Health Clinical Trials, E7 Countries (%), 2015* 17
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
Premenstrual Dysphoric Disorder (PMDD) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 25
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Premenstrual Dysphoric Disorder (PMDD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 49

Companies mentioned
Pfizer Inc.
Umecrine AB
Reviva Pharmaceuticals Inc.
Pherin Pharmaceuticals, Inc.
Novo A/S
GlaxoSmithKline Plc
CareGroup, Inc.
Berkshire Health Systems, Inc.
Bayer AG
Allergan Plc

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

Global and Chinese Progesterone Industry, 2017 Market Research Report

Global and Chinese Progesterone Industry, 2017 Market Research Report

  • $ 3000
  • Industry report
  • February 2017
  • by Prof Research

The ’Global and Chinese Progesterone Industry, 2012-2022 Market Research Report’ is a professional and in-depth study on the current state of the global Progesterone industry with a focus on the Chinese ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in China

  • February 2017
    8 pages
  • Therapy  

    Contraceptive  

  • China  

View report >

Hormone and Therapy Market in Pakistan and the US

  • February 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Insulin Market and Diabetes Statistics in the US

  • February 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.